|Ticker||Company name||Industry||Market Cap
|Dividend Yield||Dividend Frequency||Stock price||Currency||Stock Exchange|
|UCB||UCB S.A.||Healthcare||17.2||1.4 %||Annual||88.42||EUR||Euronext Brussels|
Company's Past Performance
The 5 years average P/E ratio is the average of each year’s P/E ratios. P/E ratio in any year is limited to 30 in order to reduce the effect of the extreme values on the average P/E.
UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinsonâ€™s disease, and in the area of immunology on allergies, bone loss disorders, Crohnâ€™s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, UCB maintains UCB SA delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. UCB also has a selective presence in primary care to support specialist products that are administered by primary care physicians. In May 2013, it agreed to sell its production plant in Rochester, New York, to UNITHER Pharmaceuticals.